Two new biomarkers for Alzheimer’s disease include one in the blood that relates to neurodegeneration and another that reflects blood–brain barrier dysfunction and is identifiable in cerebrospinal fluid analysis.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Cytokines and inflammatory biomarkers and their association with post-operative delirium: a meta-analysis and systematic review
Scientific Reports Open Access 06 March 2025
-
A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration
Nature Communications Open Access 25 February 2025
-
The trend of disruption in the functional brain network topology of Alzheimer’s disease
Scientific Reports Open Access 02 September 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Preische, O. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0304-3 (2019).
Nation, D.A. et al. Nat. Med. https://doi.org/10.1038/s41591-018-0297-y (2019).
Jansen, W. J. et al. JAMA Psychiatry 75, 84–95 (2018).
Ashton, N. J. et al. Biomark Med. 12, 799–812 (2018).
Fagan, A. M. et al. Sci. Transl. Med. 6, 226ra230 (2014).
Maia, L. F. et al. Sci. Transl. Med. 5, 194re192 (2013).
Sato, C. et al. Neuron 98, 861–864 (2018).
Okamura, N. et al. Clin. Transl. Imaging 6, 305–316 (2018).
Cummings, J., Lee, G., Ritter, A. & Zhong, K. Alzheimers Dement. (NY) 4, 195–214 (2018).
Rasmussen, M. K., Mestre, H. & Nedergaard, M. Lancet Neurol. 17, 1016–1024 (2018).
Khalil, M. et al. Nat. Rev. Neurol. 14, 577–589 (2018).
Bergman, J. et al. Neurol. Neuroimmunol. Neuroinflamm. 3, e271 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
H.Z. has served at scientific advisory boards of Roche Diagnostics, Wave, Samumed and CogRx and is a co-founder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures–based platform company at the University of Gothenburg. J.M.S. has received research funding and PET tracer from AVID Radiopharmaceuticals (a wholly owned subsidiary of Eli Lilly); has consulted for Roche, Eli Lilly, Biogen and Merck; received royalties from Oxford University Press and Henry Stewart Talks; given education lectures sponsored by Eli Lilly, Biogen and GE; and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE.
Rights and permissions
About this article
Cite this article
Zetterberg, H., Schott, J.M. Biomarkers for Alzheimer’s disease beyond amyloid and tau. Nat Med 25, 201–203 (2019). https://doi.org/10.1038/s41591-019-0348-z
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41591-019-0348-z
This article is cited by
-
Cytokines and inflammatory biomarkers and their association with post-operative delirium: a meta-analysis and systematic review
Scientific Reports (2025)
-
A single-cell atlas to map sex-specific gene-expression changes in blood upon neurodegeneration
Nature Communications (2025)
-
Recent Advances in Photoelectrochemical Sensing of Alzheimer’s Biomarkers
BioChip Journal (2023)
-
The trend of disruption in the functional brain network topology of Alzheimer’s disease
Scientific Reports (2022)
-
Biomarkers of Parkinson’s disease: 20 years later
Journal of Neural Transmission (2019)
